CVS Health Launches Cordavis
New business will bring high quality biosimilar
products to market with goal of reducing drug spend and ensuring access to affordable medications
Cordavis to launch
biosimilar Hyrimoz® with Sandoz beginning in 2024 at more than 80% lower list price than Humira®*
WOONSOCKET, R.I., Aug. 23, 2023 — CVS Health® (NYSE: CVS)
today announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or
co-produce biosimilar products (an FDA approved biologic medication that is highly similar to, and has no clinically meaningful differences
from, a biologic medicine already approved by the FDA) for the U.S. pharmaceutical market. The Cordavis products will be FDA approved,
high quality, and easy for patients to use and will help ensure consistent long-term supply of affordable biosimilars.
As the U.S. pharmaceutical environment continues to evolve, biosimilars
represent one of the biggest opportunities for reducing drug costs for employers and consumers. Through Cordavis, CVS Health intends to
develop a portfolio of products that it expects will facilitate broader access to biosimilars in the U.S. – creating more competition
that drives down prices – while encouraging investment in future products. The biosimilars market in the U.S. is projected to grow
from less than $10 billion in 2022 to more than $100 billion by 2029.
As its first product, Cordavis has contracted with Sandoz to commercialize
and bring to market Hyrimoz® (adalimumab-adaz), a biosimilar for Humiraâ,
in the first quarter of 2024 under a Cordavis private label. The list price of the Cordavis Hyrimoz® will be more than 80% lower
than the current list price of Humira®.
“CVS Health has a history of bringing innovative solutions to the
market that lower the cost of drugs and ensure people have access to the medications they need to stay healthy,” said Shawn Guertin,
Chief Financial Officer, CVS Health. “Cordavis is a logical evolution for us and will help ensure sufficient supply of biosimilars
in the U.S. and support this market now and in the future, while ultimately improving health outcomes and reducing costs for consumers.”
“Biosimilars are crucial to creating competition and reducing costs
for specialty pharmaceuticals where drug prices are rising the fastest,” said Prem Shah, Chief Pharmacy Officer and Co-President
of the Pharmacy and Consumer Wellness segment. “Through our direct involvement, we will expand the supply chain and ensure biosimilar
availability in the market. We have assembled a talented team at Cordavis and look forward to the value this business will deliver to
patients and payors.”
###
Cautionary Statement Concerning Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this Press Release that are forward-looking
include statements regarding potential savings opportunities and the expected pipeline of products. By their nature, all forward-looking statements are not guarantees
of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results
may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities
and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement
Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q
and our Current Reports on Form 8-K.
You are cautioned not to place undue reliance on CVS Health’s forward-looking
statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions
regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume
any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
About Hyrimoz® (adalimumab-adaz)
Adalimumab, the active ingredient in Hyrimoz, is an inhibitor
of tumor necrosis factor (TNF), a protein that is overproduced in certain autoimmune conditions — including rheumatoid arthritis,
plaque psoriasis, Crohn's disease and ulcerative colitis — causing inflammation and tissue destruction in joints, mucosa or skin.
In some cases of autoimmune disease, the immune system damages the body’s own tissues. Hyrimoz targets and blocks the protein that
contributes to disease symptoms.
INDICATIONS
HYRIMOZ® (adalimumab-adaz) is
a tumor necrosis factor (TNF)-blocker indicated for Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing
major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately
to severely active RA. HYRIMOZ can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic
drugs (DMARDs). Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular
JIA in patients 2 years of age and older. HYRIMOZ can be used alone or in combination with methotrexate. Psoriatic Arthritis (PsA): reducing
signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
HYRIMOZ can be used alone or in combination with non-biologic DMARDs. Ankylosing Spondylitis (AS): reducing signs and
symptoms in adult patients with active AS.
Crohn’s Disease (CD): treatment of moderately to severely active CD
in adults and pediatric patients 6 years of age and older. Ulcerative Colitis (UC): treatment of moderately to severely
active UC in adult patients. Limitations of Use: Effectiveness of adalimumab products has not been established in patients
who have lost response to or were intolerant to TNF-blockers. Plaque Psoriasis (Ps): treatment of adult patients with
moderate to severe chronic Ps who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically
less appropriate. HYRIMOZ should only be administered to patients who will be closely monitored and have regular follow-up visits with
a physician. Hidradenitis Suppurativa (HS): treatment of moderate to severe HS in adult patients.
SELECT
IMPORTANT SAFETY INFORMATION
WARNING:
SERIOUS INFECTIONS AND MALIGNANCY
See
full prescribing information for complete boxed warning.
SERIOUS
INFECTIONS: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial
sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue HYRIMOZ
if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB
prior to starting HYRIMOZ. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
MALIGNANCY: Lymphoma
and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab
products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and
young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
CONTRAINDICATIONS: None.
WARNINGS
AND PRECAUTIONS: Serious infections: Do not start HYRIMOZ during an active infection. If an infection develops, monitor
carefully, and stop HYRIMOZ if infection becomes serious. Invasive fungal infections: For patients who develop a systemic
illness on HYRIMOZ, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. Malignancies:
Incidence of malignancies was greater in adalimumab-treated patients than in controls. Anaphylaxis or serious hypersensitivity
reactions may occur. Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy.
If reactivation occurs, stop HYRIMOZ and begin anti-viral therapy. Demyelinating disease: Exacerbation or new onset,
may occur. Cytopenias, pancytopenia: Advise patients to seek immediate medical attention if symptoms develop, and consider
stopping HYRIMOZ. Heart failure: Worsening or new onset, may occur. Lupus-like syndrome: Stop HYRIMOZ
if syndrome develops.
ADVERSE
REACTIONS: Most common adverse reactions (>10%) are: infections (e.g. upper respiratory, sinusitis), injection site reactions,
headache and rash.
DRUG
INTERACTIONS: Abatacept: Increased risk of serious infection. Anakinra: Increased risk of serious
infection. Live vaccines: Avoid use with HYRIMOZ.
This
is not the complete list of all the safety information for HYRIMOZ. Please click to see the full Prescribing
Information for HYRIMOZ, including Boxed Warnings and Medication
Guide.
About CVS Health
CVS Health® is the leading
health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America
through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists,
nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing
chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient
ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs
and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth
on social media.
Media contact
Ethan Slavin
860-273-6095
SlavinE@cvshealth.com
Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com
*Humiraâ is a
product of AbbVie.
